| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8734779 | Seminars in Hematology | 2018 | 20 Pages |
Abstract
The treatment of the few PNH patients in which this de novo extravascular hemolysis become clinically relevant is still unsatisfactory. Nevertheless, the investigations of the mechanisms responsible of the extravascular hemolysis on eculizumab have resulted in the development of novel strategies for complement blockade that could overcome this condition.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Rosario Notaro, Michela Sica,